Benefits
Eczema and atopic dermatitis improvement
EPO's GLA content corrects the documented delta-6-desaturase enzyme deficiency in atopic dermatitis patients, restoring normal GLA and dihomo-GLA (DGLA) levels in skin lipids. Clinical studies show improvements in eczema severity, itching, scaling, and skin barrier function — with effects most pronounced in children with severe atopic dermatitis.
PMS and mastalgia relief
GLA-derived prostaglandin E1 (PGE1) has potent anti-inflammatory and pain-modulating effects in breast tissue. Clinical studies show EPO reduces cyclical breast pain (mastalgia) severity and reduces overall PMS symptom burden — particularly physical symptoms — through PGE1-mediated reduction of breast tissue prostaglandin F2α-driven inflammation.
Diabetic peripheral neuropathy improvement
Multiple clinical studies show GLA supplementation from EPO improves nerve conduction velocity, reduces neuropathic pain, and improves neurological assessments in diabetic neuropathy patients — attributed to GLA's role in restoring normal nerve membrane lipid composition and improving endoneurial blood flow.
Rheumatoid arthritis symptom reduction
EPO supplementation (at GLA doses of 1.4–2.8 g/day) significantly reduces morning stiffness, joint tenderness, and overall disease activity in rheumatoid arthritis patients. The anti-inflammatory prostaglandin E1 pathway provides complementary effects to NSAIDs and DMARDs.
Mechanism of action
Delta-6-desaturase bypass and DGLA production
Dietary linoleic acid (LA) normally requires delta-6-desaturase to convert to GLA — a step that is rate-limited and impaired in atopic, diabetic, and inflammatory conditions. GLA from EPO bypasses this bottleneck, providing direct substrate for conversion to DGLA and then to anti-inflammatory PGE1 — restoring normal eicosanoid balance without requiring the deficient enzyme.
Prostaglandin E1 synthesis and anti-inflammatory activity
DGLA (from GLA) is converted by COX-1/2 to prostaglandin E1 (PGE1) and 15-HETrE — eicosanoids with potent anti-inflammatory, vasodilatory, and platelet-inhibiting properties. PGE1 specifically opposes the inflammatory prostaglandin E2 and thromboxane A2 pathways — providing a natural anti-inflammatory mechanism that complements but is distinct from COX inhibition.
Skin barrier lipid restoration
GLA is incorporated into ceramide and phospholipid structures in the epidermal lipid barrier. In eczema patients with deficient delta-6-desaturase activity, topical and oral GLA supplementation restores normal skin lipid composition, reducing transepidermal water loss and improving the barrier function that prevents allergen penetration and inflammatory activation.
Clinical trials
Pooled analysis of clinical studies examining EPO for atopic eczema in children and adults. (— earlier; later Cochrane reviews have been more skeptical)
Pooled across multiple trials.
Earlier pooled analyses suggested EPO reduced eczema severity scores, itch, and scaling vs placebo. Critical update: the 2013 Cochrane review (Bamford et al., 27 clinical trials, ~1,596 participants) concluded EPO and borage oil have NO meaningful effect on eczema vs placebo. This led to the 2002 UK MHRA withdrawal of EPO product licenses for eczema indications. Modern dermatology guidelines do not recommend EPO for eczema. The original positive evidence appears to have been substantially industry-influenced.
Randomized, double-blind, placebo-controlled trial of GLA (480 mg/day from EPO) vs placebo in 111 diabetic neuropathy patients for 1 year. Outcomes: nerve conduction, sensory thresholds, neuropathic symptoms. (Diabetes Care)
111 diabetic neuropathy patients. 1-year intervention.
GLA improved 13 of 16 outcome measures including nerve conduction velocity vs placebo. Critical context: this was a positive trial in 1993, but subsequent larger trials and pooled analyses have not consistently replicated these findings. EPO/GLA is not recommended in current diabetic neuropathy guidelines. Modern management emphasizes glucose control plus pharmaceutical agents (duloxetine, pregabalin, gabapentin).